FASLG and hepatocellular carcinoma: From the OncoPrint, of the 440 HCC cases, amplification and mRNA upregulation were identified in FASLG, TIGIT, HAVCR2, CD27, and CD28 in 45 cases (10%), 15 cases (3%), 11 cases (2.5%), 13 cases (3%), and 15 cases (3%), respectively (Figure 1).